t Johnson & Johnson, we know that healthy people need a healthy planet.
With our reach, expertise and convening power, we are taking action to positively impact planetary health and support the resilience of our business for generations to come.
We understand that environmental impacts are increasingly affecting people’s health and well-being, and that climate change is a global public health threat. We continually strive to improve the environmental footprint of our operations, our products and our value chain. Building on more than two decades of climate action, our current climate goals are our boldest yet, and our ambition is to reach net zero carbon emissions.
As the world’s largest healthcare company, we also recognize our opportunity to drive positive change on issues that affect the health of the people we serve. Together with like-minded partners, we are working to tackle today’s global health challenges related to human and environmental health—issues like climate change and health equity.
At Johnson & Johnson, we care for the planet like our collective health depends on it … because it does.
Our environmental sustainability work is aligned with our environmental, social and governance (ESG) strategy to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Advancing environmental health is key to our vision for a sustainable future and one of three areas where the Company is uniquely positioned to achieve the greatest impact – alongside championing global health equity and empowering our employees. Learn more about our ESG strategy.
Everything we do at Johnson & Johnson is guided by Our Credo, written in 1943 by Robert Wood Johnson, which includes our commitment to “maintain in good order the property we are privileged to use, protecting the environment and natural resources.”
Cautionary Note Regarding Forward-Looking Statements: This page contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made on this page speaks only as of the date presented. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Third-party trademarks used herein are trademarks of their respective owners.